References
- Pardridge WM . Blood–brain barrier genomics. Stroke38(2), 686–690 (2007).
- Abbott NJ , PatabendigeAA, DolmanDE, YusofSR, BegleyDJ. Structure and function of the blood–brain barrier. Neurobiol. Dis.37(1), 13–25 (2010).
- Mathupala SP . Delivery of small-interfering RNA (siRNA) to the brain. Expert Opin. Ther. Pat.19(2), 137–140 (2009).
- Zlokovic BV . The blood–brain barrier in health and chronic neurodegenerative disorders. Neuron57(2), 178–201 (2008).
- Neuwelt EA , BauerB, FahlkeCet al. Engaging neuroscience to advance translational research in brain barrier biology. Nat. Rev. Neurosci. 12(3), 169–182 (2011).
- Frijns CJ , KappelleLJ. Inflammatory cell adhesion molecules in ischemic cerebrovascular disease. Stroke33(8), 2115–2122 (2002).
- Jin R , YangG, LiG. Molecular insights and therapeutic targets for blood–brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol. Dis.38(3), 376–385 (2010).
- Bonoiu A , MahajanSD, YeLet al. MMP-9 gene silencing by a quantum dot-siRNA nanoplex delivery to maintain the integrity of the blood brain barrier. Brain Res. 1282, 142–155 (2009).
- Simka M . Blood–brain barrier compromise with endothelial inflammation may lead to autoimmune loss of myelin during multiple sclerosis. Curr. Neurovasc. Res.6(2), 132–139 (2009).
- Ransohoff RM . Natalizumab for multiple sclerosis. N. Engl. J. Med.356(25), 2622–2629 (2007).
- Yan SD , ChenX, FuJet al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer‘s disease. Nature 382(6593), 685–691 (1996).
- Deane R , YanSD, SubmamaryanRKet al. RAGE mediates amyloid-β peptide transport across the blood–brain barrier and accumulation in brain. Nat. Med. 9(7), 907–913 (2003).
- Hino T , YokotaT, ItoSet al. In vivo delivery of small interfering RNA targeting brain capillary endothelial cells. Biochem. Biophys. Res. Commun.340(1), 263–267 (2006).
- Campbell M , KiangAS, KennaPFet al. RNAi-mediated reversible opening of the blood–brain barrier. J. Gene. Med. 10(8), 930–947 (2008).
- Fuest C , BankstahlM, WinterP, HelmM, PekcecA, PotschkaH. In vivo down-regulation of mouse brain capillary P-glycoprotein: a preliminary investigation. Neurosci. Lett.464(1), 47–51 (2009).
- Kuwahara H , NishinaK, YoshidaKet al. Efficient in vivo delivery of siRNA into brain capillary endothelial cells along with endogenous lipoprotein. Mol. Ther. 19(12), 2213–2221 (2011).
- Chen YH , ChangM, DavidsonBL. Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat. Med.15(10), 1215–1218 (2009).
- Uchida Y , OhtsukiS, KatsukuraYet al. Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors. J. Neurochem. 117(2), 333–345 (2011).
- Lichota J , Skj⊘rringeT, ThomsenLB, MoosT. Macromolecular drug transport into the brain using targeted therapy. J. Neurochem.113(1), 1–13 (2010).
- Kumar P , WuH, McBrideJLet al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448(7149), 39–43 (2007).
- Spencer BJ , VermaIM. Targeted delivery of proteins across the blood–brain barrier. Proc. Natl Acad. Sci. USA.104(18), 7594–7599 (2007).
- Demeule M , CurrieJC, BertrandYet al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J. Neurochem. 106(4), 1534–1544 (2008).
- Gaillard PJ , de Boer AG. 2B-trans technology: targeted drug delivery across the blood–brain barrier. Methods Mol. Biol.437, 161–175 (2008).